Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I …

JL Hsu, YF Ho, TK Li, CS Chen, LC Hsu… - Biochemical …, 2012 - Elsevier
Combination therapy, which can optimize killing activity to cancers and minimize drug
resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs) …
被引用次数：23 相关文章

Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I …

JL Hsu, YF Ho, TK Li, CS Chen… - Biochemical …, 2012 - pubmed.ncbi.nlm.nih.gov
Combination therapy, which can optimize killing activity to cancers and minimize drug
resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs) …
[HTML] nih.gov

[HTML][HTML] Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of …

JL Hsu, YF Ho, TK Li, CS Chen, LC Hsu… - Biochemical …, 2012 - ncbi.nlm.nih.gov
Combination therapy, which can optimize killing activity to cancers and minimize drug
resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs) …

Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I …

JL Hsu, YF Ho, TK Li, CS Chen, LC Hsu… - Biochemical …, 2012 - infona.pl
Combination therapy, which can optimize killing activity to cancers and minimize drug
resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs) …

Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I …

JL Hsu, YF Ho, TK Li, CS Chen, LC Hsu… - Biochemical …, 2012 - europepmc.org
Combination therapy, which can optimize killing activity to cancers and minimize drug
resistance, is a mainstream therapy against hormone-refractory prostate cancers (HRPCs) …